Anacor Pharmaceuticals, Inc. Names Paulette Dillon as Chief Business Officer
PALO ALTO, Calif., June 14 /PRNewswire/ -- Anacor Pharmaceuticals, a privately held pharmaceutical company, announced today it has hired Paulette A. Dillon as its chief business officer. In that post, Ms. Dillon will be responsible for overseeing commercial and business development.
"Paulette brings more than two decades of business experience at a variety of large and medium-sized pharmaceutical and biotech companies, and she will be an invaluable asset to the company," said David Perry, Anacor's chief executive officer. "Her past work in commercializing products, forging collaborations and negotiating licensing agreements makes her an excellent fit as Anacor expands its research and clinical programs."
Ms. Dillon most recently worked at Avidia Inc. where she served as senior vice president and chief business officer. In September 2006, Amgen purchased Avidia for $290 million in cash and as much as $90 million upon the achievement of certain. Prior to her tenure at Avidia, Ms. Dillon was the chief business officer at the Celera Genomics Group. At Celera, she oversaw commercial and business development and had responsibility for licensing and partnership efforts. She also has held the position of vice president of market and business development at Exelixis Pharmaceuticals, Inc. and vice president of strategic marketing and business development at Roche's Inflammatory Diseases Drug Discovery and Development Unit. Ms. Dillon graduated from the University of California-Los Angeles with a B.S. in kinesiology.
"Anacor has a sound development strategy for its promising anti-fungal, anti-inflammatory and antibiotic compounds," said Ms. Dillon. "I look forward to working closely with the executive team to ensure that Anacor capitalizes on the full value of its strong progress to date."
About Anacor Pharmaceuticals Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory and infectious diseases based on its proprietary, small-molecule, boron-based chemistry. AN2690, Anacor's lead product, is in Phase 2 trials for onychomycosis, a fungal infection of nails and nailbeds. Anacor has entered into an exclusive, worldwide agreement with Schering-Plough Corporation to develop and commercialize the drug. Anacor has a robust pipeline of other anti-fungal, anti-inflammatory and antibacterial compounds, including AN2728 and AN0128.Anacor Pharmaceuticals
CONTACT: David Perry, Chief Executive Officer of Anacor Pharmaceuticals,+1-650-739-0700; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, firstname.lastname@example.org, for Anacor Pharmaceuticals
Web site: http://www.anacor.com/